{"title":"Long-term prognostic role of adiponectin in stable coronary artery disease: A meta-analysis of prospective studies.","authors":"Sahas Reddy Jitta, Priyanka Vatsavayi, Chenna Reddy Tera, Shobana Krishnamurthy, Saisree Reddy Adla Jala, Diksha Sanjana Pasnoor, Utheja Dasari, Aisha Farooq, Supriya Maramreddy, Kavya Jammula, Medha Reddy Kesani, Sridevi Tripuraneni, Nihar Jena, Rupak Desai","doi":"10.4330/wjc.v17.i6.105452","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The persistent burden of cardiovascular (CV) disease in the United States requires innovative and cost-effective prognostic markers that can be relied upon.</p><p><strong>Aim: </strong>To provide insights into how adiponectin can predict all-cause mortality and major adverse CV events (MACE) in patients with coronary artery disease (CAD) and to determine the prognostic value of adiponectin in predicting all-cause mortality and MACE in patients with stable CAD.</p><p><strong>Methods: </strong>We conducted a systematic search on PubMed, Scopus, and Google Scholar to find relevant studies published through June 2023 evaluating the long-term prognostic role of adiponectin in patients with stable CAD. Using a random effects model with 95%CI, we estimated the odds ratio (OR) while assessing heterogeneity through <i>I²</i> statistics. To ensure robustness, we performed a sensitivity analysis using the leave-one-out approach.</p><p><strong>Results: </strong>After screening, we included five prospective studies involving 3225 patients who were followed up for a median duration of 3.8 years. Within the study population, prevalent risk factors included hypertension, diabetes, hyperlipidemia, and smoking. The commonly prescribed medications were angiotensin-converting enzyme inhibitors, beta blockers, and statins. The combined adjusted OR for all-cause mortality was found to be 2.51 (95%CI: 1.36-4.62), showing heterogeneity (<i>I²</i> = 65.51%, <i>P</i> = 0.03). On the other hand, the combined adjusted OR for MACE was determined to be 1.04 (95%CI: 1.02-1.06) with no significant heterogeneity observed (<i>I²</i> = 0%, <i>P</i> = 0.68). Through a sensitivity analysis, it was discovered that none of the studies significantly impacted the overall results of the meta-analysis, thus indicating their robustness.</p><p><strong>Conclusion: </strong>Higher levels of adiponectin were found to be associated with an increased risk of long-term mortality and MACE in patients with CAD, which highlights its potential as a cost-effective marker for risk assessment and guiding treatment strategies. Further research on the role of adiponectin could greatly influence decision-making and resource allocation in CV care.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 6","pages":"105452"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4330/wjc.v17.i6.105452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The persistent burden of cardiovascular (CV) disease in the United States requires innovative and cost-effective prognostic markers that can be relied upon.
Aim: To provide insights into how adiponectin can predict all-cause mortality and major adverse CV events (MACE) in patients with coronary artery disease (CAD) and to determine the prognostic value of adiponectin in predicting all-cause mortality and MACE in patients with stable CAD.
Methods: We conducted a systematic search on PubMed, Scopus, and Google Scholar to find relevant studies published through June 2023 evaluating the long-term prognostic role of adiponectin in patients with stable CAD. Using a random effects model with 95%CI, we estimated the odds ratio (OR) while assessing heterogeneity through I² statistics. To ensure robustness, we performed a sensitivity analysis using the leave-one-out approach.
Results: After screening, we included five prospective studies involving 3225 patients who were followed up for a median duration of 3.8 years. Within the study population, prevalent risk factors included hypertension, diabetes, hyperlipidemia, and smoking. The commonly prescribed medications were angiotensin-converting enzyme inhibitors, beta blockers, and statins. The combined adjusted OR for all-cause mortality was found to be 2.51 (95%CI: 1.36-4.62), showing heterogeneity (I² = 65.51%, P = 0.03). On the other hand, the combined adjusted OR for MACE was determined to be 1.04 (95%CI: 1.02-1.06) with no significant heterogeneity observed (I² = 0%, P = 0.68). Through a sensitivity analysis, it was discovered that none of the studies significantly impacted the overall results of the meta-analysis, thus indicating their robustness.
Conclusion: Higher levels of adiponectin were found to be associated with an increased risk of long-term mortality and MACE in patients with CAD, which highlights its potential as a cost-effective marker for risk assessment and guiding treatment strategies. Further research on the role of adiponectin could greatly influence decision-making and resource allocation in CV care.